Tweet
J Virol. Inhibition of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection by Anti-CD26 Monoclonal Antibody.
[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]
J Virol. 2013 Sep 25. [Epub ahead of print]
Inhibition of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection by Anti-CD26 Monoclonal Antibody.
Ohnuma K, Haagmans BL, Hatano R, Raj VS, Mou H, Iwata S, Dang NH, Jan Bosch B, Morimoto C.
Source: Department of Therapy Development and Innovation for Immune disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Abstract
We identified the domains of CD26 involved in binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 mAbs. Especially one clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 mAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. In particular, YS110 is a good candidate for immediate testing as a therapeutic modality for MERS.
PMID: 24067970 [PubMed - as supplied by publisher]
-
-------
J Virol. 2013 Sep 25. [Epub ahead of print]
Inhibition of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection by Anti-CD26 Monoclonal Antibody.
Ohnuma K, Haagmans BL, Hatano R, Raj VS, Mou H, Iwata S, Dang NH, Jan Bosch B, Morimoto C.
Source: Department of Therapy Development and Innovation for Immune disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Abstract
We identified the domains of CD26 involved in binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 mAbs. Especially one clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 mAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. In particular, YS110 is a good candidate for immediate testing as a therapeutic modality for MERS.
PMID: 24067970 [PubMed - as supplied by publisher]
-
-------